Compare AstraZeneca plc (AZN) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Kohl's Corporation — how do they compare? AstraZeneca plc trades at $168.5 (market cap $253.13B), while Kohl's Corporation trades at $17.46 (market cap $1.86B). The key difference: AstraZeneca plc is far larger — about 136.1× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (3.04%). Which is the better fit depends on your goals.
| AZN | KSS | |
|---|---|---|
Market Cap | $253.13B | $1.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $24.71 |
52-Week Low | $137.44 | $9.27 |
Enterprise Value | $279.37B | $7.97B |
Dividend Yield | 1.92% | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Kohl's (KSS) trades at $16.55, down 1.49% today, showing mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 6.95 and P/B of 0.47. Recent earnings have consistently beaten expectations, with Q1 2026 showing early turnaround progress despite revenue declines. The company maintains a 40.52% gross margin and positive cash flow from operations of $648M in 2025, while implementing strategic changes including new leadership appointments and proprietary brand expansion.
KSS presents a value opportunity with deep discount valuations, though facing significant headwinds from declining revenues and competitive pressures. The stock's near-term trajectory depends on successful execution of turnaround initiatives and proprietary brand growth, with analyst consensus at $16.75 offering modest upside potential from current levels amid cautious market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
